Cystic Fibrosis Clinical Trial
Official title:
Correlations Between CGM and Serum Glucose During OGTT Testing for CFRD
NCT number | NCT05568134 |
Other study ID # | 22-020249 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 17, 2023 |
Est. completion date | February 1, 2026 |
Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibility and accuracy of two screening tools, continuous glucose monitoring (CGM) and a home OGTT kit (GTT@home). If this pilot study reveals acceptable accuracy of either device, this study will allow for future studies exploring home-based OGTT screening.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | February 1, 2026 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of cystic fibrosis - = 10 years of age - Fluency in written and spoken English as the GTT@Home is currently only available in English Exclusion Criteria: - Hospitalization or treatment with IV antibiotics or supraphysiologic glucocorticoids within 4 weeks - Major medical or psychiatric disorders other than CF - Use of medications known to impact the accuracy of the Dexcom G7 (hydroxyurea, >2g acetaminophen per day) - History of severe adhesive reactions that may lead to an inability to tolerate CGM wear |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Philadelphia | Cystic Fibrosis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in fasting glucose will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | Fasting glucose before OGTT | |
Primary | Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in the 1 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | 1 hour mark in OGTT | |
Primary | Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose | Differences in the 2 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. | 2 hour mark in OGTT | |
Secondary | Agreement between the categorical diagnosis of normal glucose tolerance (NGT), impaired glucose tolerance (IGT), indeterminate glycemia (INDET), and CFRD as defined by plasma glucose, CGM glucose, and GTT@home glucose. | Categorical diagnosis of glucose tolerance as measured by plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose. | Up to 2 hours | |
Secondary | Difference between plasma glucose and CGM measured glucose after the fasting glucose | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the fasting glucose | |
Secondary | Difference between plasma glucose and CGM measured glucose after the 1 hour mark during the OGTT. | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the 1 hour mark in the OGTT | |
Secondary | Difference between plasma glucose and CGM measured glucose after the 2 hour mark during the OGTT. | Absolute differences between the glucose measurements will be measured in mg/dL | Up to 20 minutes after the 2 hour mark in the OGTT | |
Secondary | The ability of untrained participants to successfully complete the GTT@home kit without any guidance from the research team | Number of steps successfully completed as measured by the GTT@home instruction manual. | Up to 2 hours | |
Secondary | Impact of wearing a real-time CGM on participants' awareness of the importance of screening for and diagnosing CFRD. | 60 minute semi-structured interviews will be conducted with participants. Transcripts will be analyzed using semantic content analysis | Within 2 weeks after removal of the CGM | |
Secondary | Perceived benefits and burdens of CGM use | Participants will complete a CGM Benefits and Burdens survey, a 16-item measure used to assess perceptions of CGM technology in people with type 1 diabetes. Surveys may be completed on paper or online, as per the participant's preference. The survey is scored on a 5-point scale (agree/disagree scale). | Within 2 weeks after removal of the CGM |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |